[Pulmonary adenocarcinoma with double mutation EGFR: L858R and G719X]

Abstract

Lung cancer with EGFR mutation is rare in our country, with an estimated incidence of 7-10%. It is well known that, in this type of disease, specific inhibitors should be used, as they increase patient survival and therefore prognosis. So-called tumour heterogeneity, the possibility of various mutations concurring in the same tumour, is currently being debated. We present a case of a double mutation of EGFR and discuss treatment, management and possible implications.

Keywords: Cáncer de pulmón; EGFR mutado; EGFR mutation; Lung cancer; Next generation sequence; Secuenciación masiva.